New vaccine combo aims to boost immune attack on Hard-to-Treat cancers
NCT ID NCT02432963
First seen Jan 31, 2026 · Last updated Jun 12, 2026 · Updated 18 times
Summary
This early-stage trial tests a vaccine (p53MVA) plus the immunotherapy drug pembrolizumab in 11 adults with advanced solid tumors that have not responded to other treatments. The vaccine trains the immune system to target cancer cells with a faulty p53 gene, while pembrolizumab helps immune cells stay active. The main goal is to check safety and tolerability, with secondary goals of measuring tumor shrinkage and immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.